TENX Tenax Therapeutics Inc.

1.16
+0.02  (+2%)
Previous Close 1.14
Open 1.15
Price To Book 0.7
Market Cap 7,184,146
Shares 6,193,229
Volume 65,197
Short Ratio
Av. Daily Volume 88,180

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrolment to continue through 2019.
Levosimendan
Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF)
Phase 2b trial did not meet primary endpoint.
Levosimendan
Septic shock
Phase 3 top line data released January 31, 2017 - primary endpoints not met. Met with FDA May 10, 2017 to discuss potential NDA submission.
Levosimendan
Reduce the incidence of low cardiac output syndrome during cardiac surgery